Hosted on MSN2mon
Why Sonnet BioTherapeutics (SONN) Shares Are Down 19% Today
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) shares are trading lower by 19.9% to 72 cents Wednesday afternoon after the company announced a 1-for-8 reverse stock split. What Else ...
Business Insider29d
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic ...